



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/727.873	12/01/2000	Elizabeth M. Denholm	IT 105	7540

7590 03/27/2002

Patrea L. Pabst
Arnall Golden & Gregory, LLP
2800 One Atlantic Center
1201 West Peachtree Street
Atlanta, GA 30309-3450

EXAMINER

MELLER, MICHAEL V

ART UNIT

PAPER NUMBER

1651

DATE MAILED: 03/27/2002

4

Please find below and/or attached an Office communication concerning this application or proceeding.

Docketed for ① 4-27-02 Rm dr
By: QOS ② 5-27-02 Rm dr
Date: 4-19-02 ③ 6-27-02 Rsp w/o ext
④ 7-27-02 Rsp w/1 ext
⑤ 8-27-02 Rsp w/2 ext
⑥ 9-27-02 Rsp w/3 ext
Drop dead date

RECEIVED

APR 02 2002

PATENT DEPT.

Office Action Summary

Application No.

09/727,873

Applicant(s)

DENHOLM ET AL.

Examiner

Michael V. Meller

Art Unit

1651

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 12 December 2001.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-11 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-11 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☒ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Election/Restrictions

Applicant's election of chondroitinase B and organ fibrosis is noted. The election is still deemed to be proper and is therefore made FINAL.

Oath/Declaration

The oath is defective for the reasons of record.

Claim Rejections - 35 USC § 103

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Claims 1-11 are rejected under 35 U.S.C. 103(a) as being unpatentable over Yacoby-Zeevi (Yacoby) taken with Triscott for the reasons of record and for the reason which follow.

Applicant argues that the only data presented in Yacoby is for heparanase and that the data is confined to showing a reduction in sputum viscosity. Further, applicant argues that Yacoby does not address the issue of fibroblast proliferation nor collagen production.

Yacoby is clear that he uses chondroitinases (see col. 6, lines 55-61, cols. 7, line 65-col. 8, line 5, etc.) in his method. Further, it is also clear that Yacoby is treating the same disease as applicants and in the same way, see col. 6, lines 52-65, col. 8, lines 13-21, etc. Yacoby would inherently be performing the claimed invention since the same enzyme is being given to the same patient in the same way. It is clear from Yacoby that he wants to clear out airways. This would in fact, also decrease fibrous tissue size as claimed.

In response to applicant's arguments against the references individually, one cannot show nonobviousness by attacking references individually where the rejections are based on combinations of references. See *In re Keller*, 642 F.2d 413, 208 USPQ 871 (CCPA 1981); *In re Merck & Co.*, 800 F.2d 1091, 231 USPQ 375 (Fed. Cir. 1986).

Applicant's allege that Triscott cannot be used to teach that chondroitinase B could be used to treat patients for any disease. This is simply not true. It is well known in the scientific community that chondroitinases are well known to be used to treat diseases as is evidenced by Yacoby. Triscott was only used to provide the evidence that one of ordinary skill in the art would have been motivated to use chondroitinase B specifically since it is used so commonly as a specific type of chondroitinase.

From the teachings of the references, it is apparent that one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention. Therefore, the invention as a whole was *prima facie* obvious to one of

ordinary skill in the art at the time the invention was made, as evidenced by the references.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael V. Meller whose telephone number is 703-308-4230. The examiner can normally be reached on Monday thru Friday: 9:00am-5:30pm.


If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Wityshyn can be reached on 703-308-4743. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-0294 for regular communications and 703-308-0294 for After Final communications.

Application/Control Number:
09/727,873
Art Unit: 1651

Page 5

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

MVM
March 21, 2002


DAVID M. NAFF
PRIMARY EXAMINER
ART UNIT 1651

HOLLAND & KNIGHT LLP

One Atlantic Center
1201 West Peachtree Street, N.E.
Suite 2000
Atlanta, Georgia 30309-3400

404-817-8500
FAX 404-881-0470
http://www.hklaw.com

Annapolis
Arlington
Bethesda
Boston
Bradenton
Chicago
Fort Lauderdale
Jacksonville
Lakeland
Los Angeles
Melbourne
Miami
New York

Northern Virginia
Orlando
Portland
Providence
San Antonio
San Francisco
Seattle
St. Petersburg
Tallahassee
Tampa
Washington, D.C.
West Palm Beach

International Offices:
Caracas*
Mexico City
*Representative Office:

Rio de Janeiro
Sao Paulo
Tel Aviv*
Tokyo

FACSIMILE**TO:**

Examiner M. Meller
United States Patent and

Trademark Office

TC 1600

703 746-5254

NAME

COMPANY/FIRM

FAX NUMBER

Washington

D.C.

703 872-9305

CITY

STATE

(TELEPHONE NUMBER)

FROM:

Patrea L. Pabst

404 817-8514

16

NAME

TELEPHONE

TOTAL PAGES (Including Cover Sheet)

MESSAGE: Per our telephone conversation of today, I am refaxing the
Amendment sent on November 13, 2001, along with a Petition for One
Month Extension of Time. Thank you, Aisha Wyatt

Applicants: Elizabeth M. Denholm, Elizabeth Cauchon, and Paul J. Silver

Serial No.: 09/727,873

Art Unit: 1651

Filed: December 1, 2000

Examiner: M. Meller

For: ATTENUATION OF FIBROBLAST PROLIFERATION

Docketed for _____

By: *JDB*

Date: 12-14-01

FOR THE RECORD:

DATE: December 11, 2001

URGENCY: ☐ SUPER RUSH

☐ RUSH

☐ REGULAR

FAXED BY:

FILE #: 077818/00002

CLIENT NAME: IT 105

CONFIRMED: ☐ YES ☐ NO

NAME:

TIME:


If you did not receive all of
the pages or find that they
are illegible, please call
(404) 817-8500

CONFIDENTIALITY NOTICE: This facsimile, along with any documents, files, or
attachments, may contain information that is confidential, privileged, or otherwise
exempt from disclosure. If you are not the intended recipient or a person responsible
for delivering it to the intended recipient, you are hereby notified that any disclosure,
copying, printing, distribution or use of any information contained in or attached to
this facsimile is strictly prohibited. If you have received this facsimile in error,
please immediately notify us by facsimile or by telephone collect at the numbers
stated above, and destroy the original facsimile and its attachments without reading,
printing, or saving in any manner. Your cooperation is appreciated. Thank you.

Applicant(s):
Serial & Docket No.:
Filed:

CERTIFICATE OF TRANSMISSION UNDER 37 CFR 1.8

I hereby certify that an Amendment with Certificate of Transmission Under 37 CFR 1.8(b); Fee Transmittal; Transmittal Form PTO/SB/21; Petition for One Month Extension of Time with authorization to charge/credit the Deposit Order Account No. 50-1868; along with any paper referred to as enclosed, is being transmitted via facsimile to Examiner M. Meller at (703) 746-5254 within the United States, to the Commissioner for Patents, Washington, D.C. 20231 on the date shown below.


Aisha Wyatt

Date: December 12, 2001

ATL1 #498501 v1